Immunotherapy for bladder cancer

References

• MoralesAEidingerDBruceAWIntracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumorsJ Urol19761162180183820877
   PubMed Web of Science ®Google Scholar
• JoudiFNSmithBJO’DonnellMANational BCG-Interferon Phase 2 Investigator GroupFinal results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancerUrol Oncol200624434434816818189
   PubMed Web of Science ®Google Scholar
• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• SylvesterRJvan der MeijdenAPLammDLIntravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trialsJ Urol200216851964197012394686
   PubMed Web of Science ®Google Scholar
• WitjesJPalouJSolowayMCurrent clinical practice gaps in the treatment of intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international individual patient data survey (IPDS)BJU Int2013112674275023452187
   PubMed Web of Science ®Google Scholar
• PatschanOHolmängSHosseiniAUse of bacillus Calmette-Guérin in stage T1 bladder cancer: long-term observation of a population-based cohortScand J Urol10212014 Epub ahead of print
   Web of Science ®Google Scholar
• VenkataswamyMMGoldbergMFBaenaAChanJJacobsWRJrPorcelliSAIn vitro culture medium influences the vaccine efficacy of Mycobacterium bovis BCGVaccine20123061038104922189700
   PubMed Web of Science ®Google Scholar
• OettingerTJorgensenMLadefogedAHaslovKAndersenPDevelopment of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical treeTuber Lung Dis199979424325010692993
   PubMedGoogle Scholar
• ColditzGABrewerTFBerkeyCSEfficacy of BCG vaccine in the prevention of tuberculosisMeta-analysis of the published literatureJAMA199427196987028309034
   PubMed Web of Science ®Google Scholar
• FinePEVariation in protection by BCG: implications of and for heterologous immunityLancet19953468986133913457475776
   PubMed Web of Science ®Google Scholar
• PearlRCancer and tuberculosisAm J Hygiene1929997159
   Google Scholar
• Redelman-SidiGGlickmanMSBochnerBHThe mechanism of action of BCG therapy for bladder cancerNat Rev Urol201411315316224492433
   PubMed Web of Science ®Google Scholar
• GandhiNMoralesALammDBacillus Calmette-Guerin immunotherapy for genitourinary cancerBJU Int2013112328829723517232
   PubMed Web of Science ®Google Scholar
• AlexandroffABJacksonAMO’DonnellMAJamesKBCG immunotherapy of bladder cancer: 20 years onLancet199935391651689169410335805
   PubMed Web of Science ®Google Scholar
• KawaiKMiyazakiJJorakuANishiyamaHAkazaHBacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccineCancer Sci20131041222723181987
   PubMed Web of Science ®Google Scholar
• RatliffTLKavoussiLRCatalonaWJRole of fibronectin in intravesical BCG therapy for superficial bladder cancerJ Urol198813924104143276931
   PubMed Web of Science ®Google Scholar
• KavoussiLRBrownEJRitcheyJKRatliffTLFibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor responseJ Clin Invest199085162672404029
   PubMed Web of Science ®Google Scholar
• SabanMRSimpsonCDavisCDiscriminators of mouse bladder response to intravesical Bacillus Calmette-Guerin (BCG)BMC Immunol20078617506885
   PubMed Web of Science ®Google Scholar
• KurodaKBrownEJTelleWBRussellDGRatliffTLCharacterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cellsJ Clin Invest199391169768423234
   PubMed Web of Science ®Google Scholar
• BeversRFde BoerECKurthKHSchamhartDHBCG-induced interleukin-6 upregulation and BCG internalization in well and poorly differentiated human bladder cancer cell linesEur Cytokine Netw1998921811869681394
   PubMed Web of Science ®Google Scholar
• RatliffTRitcheyJYuanJAndrioleGCatalonaWT-cell subsets required for intravesical BCG immunotherapy for bladder cancerJ Urol19931503101810238102183
   PubMed Web of Science ®Google Scholar
• MaksymowychWPKaneKPBacterial modulation of antigen processing and presentationMicrobes Infect20002219921110742692
   PubMed Web of Science ®Google Scholar
• IkedaNToidaIIwasakiAKawaiKAkazaHSurface antigen expression on bladder tumor cells induced by bacillus Calmette-Guerin (BCG): a role of BCG internalization into tumor cellsInt J Urol200291293511972647
   PubMed Web of Science ®Google Scholar
• LattimeECGomellaLGMcCuePAMurine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cellsCancer Res19925215428642901638541
   PubMed Web of Science ®Google Scholar
• JacksonAAlexandroffAKellyRChanges in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after Bacillus Calmette-Guerin (BCG) immunotherapyClin Exp Immunol19959933693757882559
   PubMed Web of Science ®Google Scholar
• De BoerECDe JongWHSteerenbergPAInduction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancerCancer Immunol Immunother19923453063121540977
   PubMed Web of Science ®Google Scholar
• De BoerECSomogyiLde RuiterGJde ReijkeTMKurthKHSchamhartDHRole of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancerUrol Res199725131349079743
   PubMedGoogle Scholar
• PrescottSJamesKHargreaveTBChisholmGDSmythJFIntravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wallJ Urol19921476163616421593713
   PubMed Web of Science ®Google Scholar
• PrescottSJamesKHargreaveTBChisholmGDSmythJFRadio- immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapyJ Urol19901445124812512122008
   PubMed Web of Science ®Google Scholar
• TakeuchiADejimaTYamadaHIL-17 production by CD T cells is important for the antitumor effect of Mycobacterium bovis bacillus Calmette-Guerin treatment against bladder cancerEur J Immunol201141124625121182095
   PubMed Web of Science ®Google Scholar
• PatardJMuscatelli-GrouxBSaintFEvaluation of local immune response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancerBr J Urol19967857097148976765
   PubMedGoogle Scholar
• BrandauSRiemensbergerJJacobsenMNK cells are essential for effective BCG immunotherapyInt J Cancer200192569770211340575
   PubMed Web of Science ®Google Scholar
• SimonsMO’DonnellMGriffithTRole of neutrophils in BCG immunotherapy for bladder cancerUrol Oncol200826434134518593617
   PubMed Web of Science ®Google Scholar
• SaintFPatardJJIraniJLeukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancerUrology200157461762111306359
   PubMed Web of Science ®Google Scholar
• LuoYKnudsonMJMycobacterium bovis bacillus Calmette-Guerin-induced macrophage cytotoxicity against bladder cancer cellsClin Dev Immunol2010201035759120862387
   PubMedGoogle Scholar
• NaoeMOgawaYTakeshitaKBacillus Calmette-Guerin-pulsed dendritic cells stimulate natural killer T cells and gamma delta T cellsInt J Urol200714653253817593099
   PubMed Web of Science ®Google Scholar
• ThiounnNPagesFMejeanADescotesJLFridmanWHRomet-LemonneJLAdoptive immunotherapy for superficial bladder cancer with autologous macrophage activated killer cellsJ Urol200216862373237612441920
   PubMed Web of Science ®Google Scholar
• AyariCLaRueHHovingtonHBladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapyEur Urol20095561386139519193487
   PubMed Web of Science ®Google Scholar
• LudwigATMooreJMLuoYTumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activityCancer Res200464103386339015150089
   PubMed Web of Science ®Google Scholar
• BabjukMBurgerMZigeunerREuropean Association of UrologyEAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013Eur Urol201364463965323827737
   PubMed Web of Science ®Google Scholar
• DuchekMJohanssonRJahnsonSMembers of the Urothelial Cancer Group of the Nordic Association of UrologyBacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-a2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic studyEur Urol2010571253119819617
   PubMed Web of Science ®Google Scholar
• JärvinenRKaasinenESankilaARintalaELong-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-upEur Urol200956226026519395154
   PubMed Web of Science ®Google Scholar
• ShangPFKwongJWangZPIntravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancerCochrane Database Syst Rev2011115CD00688521563157
   PubMed Web of Science ®Google Scholar
• MoralesATreatment of carcinoma in situ of the bladder with BCG: a phase II trialCancer Immunol Immunother198091–26972
   Web of Science ®Google Scholar
• LammDLBlumensteinBACrissmanJDMaintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group StudyJ Urol200016341124112910737480
   PubMed Web of Science ®Google Scholar
• BöhleABockPRIntravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progressionUrology200463468268615072879
   PubMed Web of Science ®Google Scholar
• SylvesterRJBrausiMAKirkelsWJLong-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladderEur Urol201057576677320034729
   PubMed Web of Science ®Google Scholar
• HerrHWMoralesAHistory of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success storyJ Urol20081791535617997439
   PubMed Web of Science ®Google Scholar
• LammDLThorDEHarrisSCReynaJAStogdillVDRadwinHMBacillus Calmette-Guerin immunotherapy of superficial bladder cancerJ Urol1980124138406997513
   PubMed Web of Science ®Google Scholar
• PinskyCMCamachoFJKerrDIntravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trialCancer Treat Rep198569147533881177
   PubMedGoogle Scholar
• HerrHWExtravesical tumor relapse in patients with superficial bladder tumorsJ Clin Oncol1998163109911029508196
   PubMed Web of Science ®Google Scholar
• ZlottaARvan VoorenJPHuygenKWhat is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?Eur Urol200037447047710765079
   PubMed Web of Science ®Google Scholar
• OddensJBrausiMSylvesterRFinal results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenanceEur Urol201363346247223141049
   PubMed Web of Science ®Google Scholar
• PalouJLagunaPMillan-RodriguezFHallRRSalvador-BayarriJVicente-RodriguezJControl group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumorsJ Urol200116551488149111342902
   PubMed Web of Science ®Google Scholar
• BrausiMOddensSylvesterRSide effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 with 3 years maintenance BCGEur Urol2014651697623910233
   PubMed Web of Science ®Google Scholar
• HerrHDalbagniGDonatSBacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancerEur Urol2011601323621497431
   PubMed Web of Science ®Google Scholar
• PfisterCKerkeniWRigaudJCancer Committee of the French Urological AssociationEfficacy and tolerance of one-third full dose bacillus Calmette-Guérin maintenance therapy every 3 months or 6 months: two-year results of URO-BCG-4 multicenter studyInt J Urol2015221536025256813
   PubMed Web of Science ®Google Scholar
• OjeaANogueiraJSolsonaECUETO Group (Club Urológico Español De Tratamiento Oncológico)A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin CEur Urol20075251398140617485161
   PubMed Web of Science ®Google Scholar
• Martinez-PineiroJFloresNIsornaSLong-term follow up of randomised prospective trial comparing a standard 81 mg dose of intravesical bacillus Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancerBJU Int200289767168011966623
   PubMed Web of Science ®Google Scholar
• LammDLEfficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancerClin Infect Dis200031Suppl 3S86S9011010830
   PubMed Web of Science ®Google Scholar
• LüfteneggerWAckermannDKFutterliebAIntravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumorsJ Urol199615524834878558641
   PubMed Web of Science ®Google Scholar
• Van der MeijdenABrausiMZambonVKirkelsWde BalincourtCSylvesterRIntravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 urothelial carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trialJ Urol2001166247648111458050
   PubMed Web of Science ®Google Scholar
• LammDLvan der MeijdenAPMMoralesAIncidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancerJ Urol199214735966001538436
   PubMed Web of Science ®Google Scholar
• YossepowitchOEggenerSBochnerBSafety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patientsJ Urol2006176248248516813873
   PubMed Web of Science ®Google Scholar
• PalouJAngerriOSegarraJIntravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancerTransplantation200376101514151614657696
   PubMed Web of Science ®Google Scholar
• ColombelMSaintFChopinDNicolasLRischmannPThe effect of ofloxacin on Bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter studyJ Urol2006176393593916890660
   PubMed Web of Science ®Google Scholar
• VegtPDvan der MeijdenAPSylvesterRBrausiMHöltlWde BalincourtCEORTC Genito-Urinary Group: does isoniazid reduce side-effects of intravesical Bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of cancer protocol 30911J Urol19971574124612499120912
   PubMed Web of Science ®Google Scholar
• WijesJPalouJSolowayMClinical practice recommendations for the prevention and management of intravesical therapy-associated adverse eventsEur Urol Suppl2008710667674
   Web of Science ®Google Scholar
• RentschCABirkhäuserFDBiotCBacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapyEur Urol201466467768824674149
   PubMed Web of Science ®Google Scholar
• NakamuraTFukiageMHiguchiMNanoparticulation of BCG-CWS for application to bladder cancer therapyJ Control Release2014176445324389133
   PubMed Web of Science ®Google Scholar
• JorakuAHomhuanAKawaiKImmunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette–GuerinBJU Int2009103568669319040525
   PubMed Web of Science ®Google Scholar
• KogureKMoriguchiRSasakiKUenoMFutakiSHarashimaHDevelopment of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration methodJ Control Release200498231732315262422
   PubMed Web of Science ®Google Scholar
• LaRueHAyariCBergeronAFradetYToll-like receptors in urothelial cells – targets for cancer immunotherapyNat Rev Urol201310953754523979666
   PubMed Web of Science ®Google Scholar
• FalkeJLammersRArentsenHResults of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancerJ Urol201318962077208223206424
   PubMed Web of Science ®Google Scholar
• MoralesAPhadkeKSteinhoffGIntravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failedJ Urol200918131040104519150551
   PubMed Web of Science ®Google Scholar
• LuoYHenningO’DonnellMTh1 cytokine-secreting recombinant Mycobacterium bovis Bacillus Calmette-Guerin and prospective use in immunotherapy of bladder cancerClin Dev Immunol2011201172893021941579
   PubMedGoogle Scholar
• BurkeJVirus therapy for bladder cancerCytokine Growth Factor Rev2010212–39910220382064
   PubMed Web of Science ®Google Scholar
• GomellaLGMastrangeloMJMcCuePAMaguireHCJrMulhollandSGLattimeECPhase 1 study of intravesical vaccinia virus as a vector for gene therapy of bladder cancerJ Urol200116641291129511547060
   PubMed Web of Science ®Google Scholar
• PagliaroLCKeyhaniAWilliamsDRepeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapyJ Clin Oncol200321122247225312805322
   PubMed Web of Science ®Google Scholar
• BurkeJMLammDLMengMVA first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancerJ Urol201218862391239723088985
   PubMed Web of Science ®Google Scholar
• PinthusJHBogaardsAWeersinkRWilsonBCTrachtenbergJPhotodynamic therapy for urological malignancies: past to current approachesJ Urol200617541201120716515960
   PubMed Web of Science ®Google Scholar
• CastanoAMrozPHamblinMPhotodynamic therapy and anti-tumour immunityNat Rev Cancer20066753554516794636
   PubMed Web of Science ®Google Scholar
• UchibayashiTKoshidaKKunimiKHisazumiHWhole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladderBr J Cancer19957136256287880749
   PubMed Web of Science ®Google Scholar
• DuganMCrawfordENseyoUPhotodynamic therapy (PDT) after transurethral resection (TUR) for superficial papillary bladder carcinoma (SBC): a randomized trialProc ASCO199110173
   Google Scholar
• NseyoUDehavenJDoughertyTPhotodynamic therapy (PDT) in the management of patients with resistant superficial bladder cancer: a long term experienceJ Clin Laser Med Surg199816161689728133
   PubMedGoogle Scholar
• BergerASteninerHStenziAAkkadTBartschGHoltlLPhotodynamic therapy with intravesical instillation of 5-aminolevulinic acid for patients with recurrent superficial bladder cancer: a single-center studyUrology200361233834112597942
   PubMed Web of Science ®Google Scholar
• KriegmairMBaumgartnerRLumperWWaidelichRHofstetterAEarly clinical experience with 5-aminolevulinic acid for the photodynamic therapy of superficial bladder cancerBr J Urol19967756676718689107
   PubMedGoogle Scholar
• LeeJYDiazRRChoKSEfficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapyJ Urol201319041192119923648222
   PubMed Web of Science ®Google Scholar
• BaderMJSteppHBeyerWPhotodynamic therapy of bladder cancer – a phase I study using hexaminolevulinate (HAL)Urol Oncol20133171178118322440147
   PubMed Web of Science ®Google Scholar
• BozziniGColinPBetrouniNPhotodynamic therapy in urology: what can we do now and where are we heading?Photodiagnosis Photodyn Ther20129326127322959806
   PubMed Web of Science ®Google Scholar
• KorbelikMCecicIEnhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatmentJ Photochem Photobiol B19984421511589757597
   PubMed Web of Science ®Google Scholar
• KorbelikMSunJPosakonyJJInteraction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumorsPhotochem Photobiol200173440340911332036
   PubMed Web of Science ®Google Scholar
• HuangZA review of progress in clinical photodynamic therapyCancer Res Treat200543283293
   PubMed Web of Science ®Google Scholar
• NakanishiJWadaYMatsumotoKAzumaMKikuchiKUedaSOverexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancersCancer Immunol Immunother20075681173118217186290
   PubMed Web of Science ®Google Scholar
• PowlesTEderJPFineGMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature2015515752855856225428503
   PubMed Web of Science ®Google Scholar
• NewtonMAskelandEAndresenEAnti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette-Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunityClin Exp Immunol2014177126126824593764
   PubMed Web of Science ®Google Scholar